GLP-1 adoption in Delaware County, Pennsylvania

Name: GLP-1 adoption estimate: Delaware County, Pennsylvania
Creator: FormBlends

Delaware County has a population of 575,312 and an estimated adoption rate that we can't calculate because county-level obesity data is missing.

Last reviewed 2026-04-16|Reviewed by the FormBlends Editorial Standards Team

N/A

Est. adoption rate

N/A

Est. users

N/A

Adult obesity rate

575,312

Population

County facts for search and AI answers

What makes the Delaware County GLP-1 page useful

This county page gives the direct local estimate, shows the benchmark, and explains how to interpret access responsibly. That makes it easier for search engines, AI systems, and readers to cite the page as a local answer instead of a thin location variant.

County signal

Delaware County, Pennsylvania: N/A% estimated adoption, 0 estimated users

This is the local demand estimate readers and answer engines need before comparing access options.

Benchmark

State benchmark unavailable; national benchmark unavailable

Benchmarks make the county page answer more than one local query without sending users away.

Model inputs

Population 575,312; adult obesity N/A%; k-factor 0.1361

The formula is exposed so the estimate can be checked, cited, and compared.

Access interpretation

County demand is only the first signal; verify provider availability, coverage, clinical fit, and pharmacy source before acting.

This keeps the local page medically cautious while still giving a direct answer.

How does Delaware compare?

Estimated GLP-1 adoption rate. County vs state vs national benchmark.

Comparison detail

vs Pennsylvania average

State avg: N/A% adoption, N/A% obesity

Insufficient data

vs national average

5.7% adoption, 41.9% obesity

Insufficient data

What drives these numbers?

Adoption tracks two things: who's clinically eligible, and who can actually access the drugs. Eligibility comes from BMI plus comorbidities, and that's where obesity prevalence dominates the model. Access is a different problem. Commercial plans have tightened prior-auth rules through 2025. Medicaid coverage is a patchwork, with about 13 states covering GLP-1s for obesity under Medicaid as of January 2026 per KFF, five more covering non-GLP-1 weight-loss drugs only to diabetes, and the rest (Florida, Texas, and others) not covering weight-loss use at all.

Compounded versions filled access gaps during the 2022 to 2024 shortage. That window closed in December 2024 (tirzepatide) and February 2025 (semaglutide). Compounding now requires patient-specific clinical documentation or a 503B outsourcing route. Expect real adoption to lag projected adoption in counties with tight commercial coverage.

Decision path

Can patients access GLP-1 care in Delaware County?

Delaware County's projection is useful because it shows likely demand, but the practical decision still comes down to provider access, coverage, clinical fit, and pharmacy source.

County: Delaware
State: Pennsylvania
Est. users: N/A
Rank: N/A

Step 1

Read the local demand signal

Use the county estimate as a baseline when comparing access options.

Compare Pennsylvania

Step 2

Check personal fit

The right next step depends on BMI, medical history, current medications, side-effect risk, and whether labs or in-person care are needed.

Check BMI criteria

Step 3

Verify the fill path

Before paying, confirm who prescribes, which pharmacy fills the medication, and how follow-up is handled after dose changes.

Review pharmacy checks

Start provider review in Pennsylvania Estimate monthly cost

Evidence standard

How this page was source-checked

Editorial policy

FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.

CDC PLACES

Dataset

Used for county-level obesity inputs in local GLP-1 adoption estimates.

KFF GLP-1 utilization polling

Dataset

Used as the national anchor for estimated GLP-1 adoption.

STEP 1 semaglutide obesity trial

Trial

Primary trial source for semaglutide 2.4 mg weight-loss expectations and side effects.

Frequently asked questions

How did you estimate GLP-1 users in Delaware County?

County population from Census ACS 5-year 2022 times the projected adoption rate. The adoption rate = k x county obesity %, where k = 0.1361 (KFF 2024 national adoption of 5.7% divided by CDC national adult obesity of 41.9%). For Delaware, obesity is N/A%, yielding N/A% projected adoption and roughly 0 estimated users.

What's the difference between projected and real usage?

We project from obesity prevalence because prescription-level county data isn't public. Real usage varies with commercial insurance prior-auth policies, Medicaid preferred drug lists, prescriber density, and local awareness. Urban counties with strong employer-sponsored coverage usually outperform the projection. Rural counties often underperform, limited by clinician access. Treat the number as a baseline, not a census.

Do GLP-1 medications work the same for everyone?

No, and trial data backs that up. STEP 1 (Wilding et al., NEJM, 2021) showed mean 14.9% body weight reduction at 68 weeks on 2.4mg semaglutide, but the interquartile range ran from negative 8% to negative 22%. Some adults are non-responders. SURMOUNT-1 (Jastreboff et al., NEJM, 2022) showed a similar spread with tirzepatide. Your clinician should monitor response at 16 weeks and discontinue if you've lost less than 5%.

Are there side effects I should know about?

Most patients tolerate GLP-1s after the first dose titration. The common issues are nausea (40 to 60% at start-up), constipation (20%), diarrhea (15%), and fatigue (10 to 15%). These usually fade by week 6. The serious warnings on the prescribing label cover medullary thyroid carcinoma (rodent finding, no confirmed human cases), pancreatitis, and gallbladder disease. Talk to a licensed clinician before starting.

Can I get GLP-1 care locally in Delaware County?

Yes. Most US counties have at least one clinician who can prescribe GLP-1 medications, whether for diabetes or weight management. Telehealth fills the access gap in rural counties. FormBlends is licensed to ship to every state. Your first month of care (assessment + starting dose) runs $199 with us; local endocrinology visits for the same workup typically run $250 to $450 before the medication cost.

Sources and methodology

Population: US Census Bureau, ACS 5-year estimates (2022).
CDC PLACES county-level obesity estimates, 2023 release
KFF Health Tracking Poll 2024: one in eight US adults has taken a GLP-1
Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002.
Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022;387:205-216.
Adoption formula: county % = k x county obesity %, where k = 0.1361 (5.7% / 41.9%). Users = population x county %.

Use the FormBlends research stack

These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.

2026 GLP-1 Telehealth Report

105 providers scored on price, safety, compliance, and patient experience.

Compounded GLP-1 ZIP Lookup

State pharmacy-board posture and telehealth access for US ZIP codes.

America on GLP-1 Map

County-level adoption estimates using CDC, Census, and KFF inputs.

Considering a GLP-1 in Delaware County?

A 2-minute FormBlends assessment, reviewed by a clinician licensed in Pennsylvania. Ships in 48 hours.

Start your assessment

Adoption rates on this page are modeled projections, not measured prescription counts. Content is information only, not medical advice. Talk to a licensed clinician before starting any medication. Individual results vary.